An Open-label, Single Arm, Multicenter Extension Study to Evaluate Long-term Safety and Tolerability of Inclisiran in Participants With Heterozygous or Homozygous Familial Hypercholesterolemia Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20 or ORION-19 Studies (VICTORION-PEDS-OLE)
Status: Recruiting
Location: See all (50) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who have completed the ORION-16 (CKJX839C12301), ORION-13 (CKJX839C12302), ORION-20 (CKJX839C12303) or ORION-19 (CKJX839C12304) studies.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 100
Healthy Volunteers: f
View:
• Male and female participants with a diagnosis of HeFH or HoFH who completed the ORION-16, ORION-13, ORION-20 or ORION-19 studies
• Per investigator's clinical judgment, participant derived benefit from treatment with inclisiran in the ORION-16, ORION-13, ORION-20 or ORION-19 studies
Locations
United States
Florida
Excel Medical Clinical Trials LLC
COMPLETED
Boca Raton
New York
Icahn School of Med at Mt Sinai
ACTIVE_NOT_RECRUITING
New York
Ohio
Cincinnati Childrens Hospital MC
COMPLETED
Cincinnati
Pennsylvania
Childrens Hosp Pittsburgh UPMC
COMPLETED
Pittsburgh
Utah
Primary Childrens Medical Center
RECRUITING
Salt Lake City
Other Locations
Argentina
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Formosa
Brazil
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Fortaleza
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
São Paulo
Novartis Investigative Site
COMPLETED
São Paulo
Canada
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Québec
France
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Besançon
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Toulouse
Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Frankfurt Am Main
Novartis Investigative Site
COMPLETED
Freiburg Im Breisgau
Greece
Novartis Investigative Site
COMPLETED
Athens
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Athens
Hungary
Novartis Investigative Site
COMPLETED
Pécs
Israel
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Jerusalem
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Ramat Gan
Italy
Novartis Investigative Site
COMPLETED
Milan
Novartis Investigative Site
COMPLETED
Modena
Novartis Investigative Site
COMPLETED
Roma
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Roma
Jordan
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Irbid
Lebanon
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Beirut
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Beirut
Malaysia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Kuala Lumpur
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Sungai Buloh
Netherlands
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Amsterdam
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Rotterdam
Norway
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Oslo
Poland
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Gdansk
Novartis Investigative Site
COMPLETED
Lodz
Russian Federation
Novartis Investigative Site
COMPLETED
Kemerovo
Novartis Investigative Site
COMPLETED
Moscow
Slovakia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Poprad
Slovenia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Ljubljana
South Africa
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Bloemfontein
Novartis Investigative Site
COMPLETED
Cape Town
Spain
Novartis Investigative Site
COMPLETED
A Coruña
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Córdoba
Novartis Investigative Site
COMPLETED
Oviedo
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Pamplona
Switzerland
Novartis Investigative Site
COMPLETED
Geneva
Taiwan
Novartis Investigative Site
RECRUITING
Taipei
Turkey
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Adana
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Ankara
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Istanbul
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Izmir
United Kingdom
Novartis Investigative Site
ACTIVE_NOT_RECRUITING
Middlesex
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
1-888-669-6682
Backup
Novartis Pharmaceuticals
+41613241111
Time Frame
Start Date: 2023-02-10
Estimated Completion Date: 2032-03-28
Participants
Target number of participants: 195
Treatments
Experimental: Inclisiran
Participants who have completed ORION-16 or ORION-13 receive inclisiran sodium 300mg (equivalent to 284mg inclisiran\*) in 1.5mL solution.~Participants who have completed ORION-19 and ORION-20 receive Inclisiran dose levels based on weight.
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals